A Phase 2 interventional study of Vedolizumab in Allogeneic Hematopoietic Stem Cell Transplantation, sponsored by Millennium Pharmaceuticals, Inc.. Terminated at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-24.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the initial activity, tolerability, safety and to identify a recommended dose and regimen of vedolizumab intravenous (IV) administered for treatment of steroid-refractory acute intestinal GvHD in participants who have undergone allo-HSCT.
The drug being tested in this study is called vedolizumab. This study will look at the tolerability and effectiveness of vedolizumab IV in participants with acute intestinal GvHD who have received no systemic therapy for the treatment of acute GvHD (prophylaxis acceptable) other than corticosteroids.
The study enrolled 17 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups:
All participants will be infused intravenously at the same time each day throughout the study. Vedolizumab IV will be administered on Days 1, 15, 43, 71, and 99. After approximately 10 participants are enrolled at each dose level and have data available from the Day 28 evaluation, safety, tolerability, efficacy, and pharmacokinetic (PK), results will be assessed for each dose level, and the appropriate dose for subsequent participants in the study will be determined.
This multi-center trial will be conducted in multiple countries. The overall time to participate in this study is 32 weeks. Participants will make multiple visits to the clinic after last dose of study drug for a follow-up assessment.
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vedolizumab 300 mg, intravenous (IV) infusion, once on Days 1, 15, 43, 71 and 99.
Drug: Vedolizumab
Vedolizumab 600 mg, IV infusion, once on Days 1, 15, 43, 71 and 99.
Drug: Vedolizumab
Vedolizumab IV infusion
Also known as: Entyvio, MLN0002
Percentage of Participants With Overall Response (Partial Response [PR]+Very Good Partial Response [VGPR]+Complete Response [CR]) at Day 28
CR is defined as the resolution of all signs and symptoms of acute graft-versus-host-disease (GvHD). VGPR is defined as resolution of the signs and symptoms of the GvHD: 1) Skin: no rash, or residual erythematous rash involving \<25% of the body surface, without bullae (excluding residual faint erythema and hyperpigmentation). 2) Liver: total serum bilirubin concentration \<2 mg/dL or \<25% of baseline at enrollment. 3) Gut: a) participant tolerates food or enteral feeding; b) predominantly formed stools; c) no overt gastrointestinal bleeding or abdominal cramping; d) no more than occasional nausea or vomiting. PR is defined as improvement of 1 GvHD stage in 1 or more organs without progression in any organ.
Time frame: Day 28
Number of Participants Who Experienced Serious Adverse Events (SAEs) Through Day 28
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as an untoward medical occurrence, significant hazard, contraindication, side effect or precaution that at any dose: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: From first dose up to Day 28
Percentage of Participants Who Died in the Absence of Primary Malignancy Relapse After Allo-HSCT at Month 6
Time frame: Month 6
Percentage of Participants With Acute GvHD Complete Response (CR) at Day 28
CR is defined as the resolution of all signs and symptoms of acute GvHD.
Time frame: Day 28
Percentage of Participants With Intestinal Overall Response at Day 28
Symptoms of acute intestinal GvHD were measured using the BMT CTN-modified International Bone Marrow Transplant Registry Database (IBMTR) index. Intestinal overall response is either CR, VGPR or PR for intestine only. CR is defined as the resolution of all signs and symptoms of GvHD. VGPR is defined as resolution of the majority of signs and symptoms of intestinal GvHD: a) participant tolerates food or enteral feeding; b) predominantly formed stools; c) no overt gastrointestinal bleeding or abdominal cramping; d) no more than occasional nausea or vomiting. PR is defined as improvement of intestinal GvHD by at least 1 stage.
Time frame: Day 28
Kaplan-Meier Estimate of Percentage of Participants Achieving Survival at Months 6 and 12
The Kaplan-Meier estimate reports the percentage of participants surviving at Months 6 and 12.
Time frame: Months 6 and 12
Percentage of Participants Alive Without GvHD or Primary Malignancy Relapse at Months 6 and 12
Time frame: Months 6 and 12
Total Dose of Steroids Administered
Total Steroids administered in mg/kg/day of methylprednisolone or equivalent
Time frame: From first dose of study drug up to Months 6 and 12
Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From first dose of study drug to 18 weeks after last dose (Up to Week 32)
Number of Participants Who Experienced Serious Adverse Events (SAEs) Through Week 32
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as an untoward medical occurrence, significant hazard, contraindication, side effect or precaution that at any dose: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: From first dose of study drug to 18 weeks after last dose (Up to Week 32)
Number of Participants With Markedly Abnormal Laboratory Parameters Values
Clinical Laboratory parameters included tests for chemistry, hematology and urinalysis. Markedly abnormal values during treatment period were categorized as:alanine aminotransferase (ALT)\>3.0 U/L\*upper limit of normal(ULN),albumin\<25 g/L\*lower limit of normal(LLN),alkaline phosphatase \>3.0 U/L\*ULN,aspartate aminotransferase \>3.0 U/L\*ULN,bilirubin \>2 umol/L\*ULN,blood urea nitrogen(BUN) \>10.7 mmol/L,calcium \<1.75 mmol/L, \>2.88 mmol/L,chloride \<75 mmol/L, \>126 mmol/L,creatinine \>177umol/L,gamma glutamyl transferase (GGT) \>3 U/L\*ULN,glucose \<2.8 mmol/L, \>19.4 mmol/L,phosphate \<0.52 mmol/L, \>2.10 mmol/L,potassium\<3 mmol/L, \>6 mmol/L,sodium \<130 mmol/L, \>150 mmol/L,basophils \>3(10\^9/L)\*ULN,eosinophils \>2(10\^9/L)\*ULN,hematocrit (%) \<0.8\*LLN, \>1.2\*ULN,hemoglobin \<0.8 g/L\*LLN, \>1.2 g/L\*ULN,leukocytes \<0.5 (10\^9/L)\*LLN, \>1.5 (10\^9/L)\*ULN,lymphocytes \<0.5 (10\^9/L)\*LLN, \>1.5(10\^9/L)\*ULN,monocytes \>2 (10\^9/L)\*ULN,neutrophils \<0.5(10\^9/L)\*LLN, \>1.5 (10\^9/L)\*ULN,platelets \<75(10\^9/L), \>600(10\^9/L).
Time frame: From Baseline up to last dose of study drug (Day 99)
Number of Participants With Markedly Abnormal Vital Signs
Vital signs included heart rate, respiratory rate, systolic and diastolic blood pressure, temperature and weight. The vital sign values outside the range: systolic blood pressure (SBP) \<85 mmHg and change from Baseline (BL) \<=-20 mmHg, \>180 mmHg and change from Baseline \>=20 mmHg,diastolic blood pressure (DBP) \<50 mmHg and change from Baseline \<=-15 mmHg, \>110 mmHg and change from Baseline \>=15 mmHg, heart rate \<50 beats per minute (bpm),\>120 beats per minute, temperature \<35.6 Degree C, \>37.7 Degree C and weight change from Baseline \<=-7 % and weight change from Baseline \>=7 % assessed during treatment period were considered markedly abnormal.
Time frame: From Baseline up to last dose of study drug (Day 99)
Ctrough: Trough Serum Concentrations of Vedolizumab
Time frame: Day 99 (pre-dose)
Participants took part in the study at 11 investigative sites in the United States, France, Belgium and Norway from 28 April 2017 to 09 May 2018.
| Milestone | Vedolizumab 300 mg | Vedolizumab 600 mg |
|---|---|---|
| Started | 8 | 9 |
| Completed | 2 | 0 |
| Not completed | 6 | 9 |
| Withdrew: Reason not specified | 6 | 9 |
CR is defined as the resolution of all signs and symptoms of acute graft-versus-host-disease (GvHD). VGPR is defined as resolution of the signs and symptoms of the GvHD: 1) Skin: no rash, or residual erythematous rash involving \<25% of the body surface, without bullae (excluding residual faint erythema and hyperpigmentation). 2) Liver: total serum bilirubin concentration \<2 mg/dL or \<25% of baseline at enrollment. 3) Gut: a) participant tolerates food or enteral feeding; b) predominantly formed stools; c) no overt gastrointestinal bleeding or abdominal cramping; d) no more than occasional nausea or vomiting. PR is defined as improvement of 1 GvHD stage in 1 or more organs without progression in any organ.
| percentage of participants | Vedolizumab 300 mg | Vedolizumab 600 mg |
|---|---|---|
| Percentage of Participants With Overall Response (Partial Response [PR]+Very Good Partial Response [VGPR]+Complete Response [CR]) at Day 28 | 50.0 (15.7 to 84.3) | 22.2 (2.8 to 60.0) |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as an untoward medical occurrence, significant hazard, contraindication, side effect or precaution that at any dose: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
| Participants | Vedolizumab 300 mg | Vedolizumab 600 mg |
|---|---|---|
| Number of Participants Who Experienced Serious Adverse Events (SAEs) Through Day 28 | 3 | 4 |
| percentage of participants | Vedolizumab 300 mg | Vedolizumab 600 mg |
|---|---|---|
| Percentage of Participants Who Died in the Absence of Primary Malignancy Relapse After Allo-HSCT at Month 6 | 50.0 (15.7 to 84.3) | 88.9 (68.4 to 100.0) |
CR is defined as the resolution of all signs and symptoms of acute GvHD.
| percentage of participants | Vedolizumab 300 mg | Vedolizumab 600 mg |
|---|---|---|
| Percentage of Participants With Acute GvHD Complete Response (CR) at Day 28 | 12.5 (0.3 to 52.7) | 0 (0 to 0) |
Symptoms of acute intestinal GvHD were measured using the BMT CTN-modified International Bone Marrow Transplant Registry Database (IBMTR) index. Intestinal overall response is either CR, VGPR or PR for intestine only. CR is defined as the resolution of all signs and symptoms of GvHD. VGPR is defined as resolution of the majority of signs and symptoms of intestinal GvHD: a) participant tolerates food or enteral feeding; b) predominantly formed stools; c) no overt gastrointestinal bleeding or abdominal cramping; d) no more than occasional nausea or vomiting. PR is defined as improvement of intestinal GvHD by at least 1 stage.
| percentage of participants | Vedolizumab 300 mg | Vedolizumab 600 mg |
|---|---|---|
| Percentage of Participants With Intestinal Overall Response at Day 28 | 62.5 (24.5 to 91.5) | 33.3 (7.5 to 70.1) |
The Kaplan-Meier estimate reports the percentage of participants surviving at Months 6 and 12.
| percentage of participants | Vedolizumab 300 mg | Vedolizumab 600 mg |
|---|---|---|
| Month 6 | 0.50 (0.15 to 0.77) | 0.11 (0.01 to 0.39) |
| Month 12 | NA (NA to NA) | NA (NA to NA) |
| percentage of participants | Vedolizumab 300 mg | Vedolizumab 600 mg |
|---|---|---|
| Month 6 | 37.5 | 0 |
| Month 12 | 0 | 0 |
Total Steroids administered in mg/kg/day of methylprednisolone or equivalent
| mg/kg/day | Vedolizumab 300 mg | Vedolizumab 600 mg |
|---|---|---|
| Month 6 | 0.862 ± 0.6397 | 0.876 ± 0.4796 |
| Month 12 | 0.829 ± 0.6611 | 0.876 ± 0.4798 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
| Participants | Vedolizumab 300 mg | Vedolizumab 600 mg |
|---|---|---|
| Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs) | 8 | 9 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as an untoward medical occurrence, significant hazard, contraindication, side effect or precaution that at any dose: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
| Participants | Vedolizumab 300 mg | Vedolizumab 600 mg |
|---|---|---|
| Number of Participants Who Experienced Serious Adverse Events (SAEs) Through Week 32 | 6 | 9 |
Clinical Laboratory parameters included tests for chemistry, hematology and urinalysis. Markedly abnormal values during treatment period were categorized as:alanine aminotransferase (ALT)\>3.0 U/L\*upper limit of normal(ULN),albumin\<25 g/L\*lower limit of normal(LLN),alkaline phosphatase \>3.0 U/L\*ULN,aspartate aminotransferase \>3.0 U/L\*ULN,bilirubin \>2 umol/L\*ULN,blood urea nitrogen(BUN) \>10.7 mmol/L,calcium \<1.75 mmol/L, \>2.88 mmol/L,chloride \<75 mmol/L, \>126 mmol/L,creatinine \>177umol/L,gamma glutamyl transferase (GGT) \>3 U/L\*ULN,glucose \<2.8 mmol/L, \>19.4 mmol/L,phosphate \<0.52 mmol/L, \>2.10 mmol/L,potassium\<3 mmol/L, \>6 mmol/L,sodium \<130 mmol/L, \>150 mmol/L,basophils \>3(10\^9/L)\*ULN,eosinophils \>2(10\^9/L)\*ULN,hematocrit (%) \<0.8\*LLN, \>1.2\*ULN,hemoglobin \<0.8 g/L\*LLN, \>1.2 g/L\*ULN,leukocytes \<0.5 (10\^9/L)\*LLN, \>1.5 (10\^9/L)\*ULN,lymphocytes \<0.5 (10\^9/L)\*LLN, \>1.5(10\^9/L)\*ULN,monocytes \>2 (10\^9/L)\*ULN,neutrophils \<0.5(10\^9/L)\*LLN, \>1.5 (10\^9/L)\*ULN,platelets \<75(10\^9/L), \>600(10\^9/L).
| Participants | Vedolizumab 300 mg | Vedolizumab 600 mg |
|---|---|---|
| ALT >3.0 U/L*ULN | 4 | 0 |
| Albumin <25 g/L*LLN | 4 | 8 |
| Alkaline phosphatase >3.0 U/L*ULN | 1 | 0 |
| Aspartate aminotransferase >3.0 U/L*ULN | 1 | 0 |
| Bilirubin >2 umol/L*ULN | 1 | 2 |
| BUN >10.7 mmol/L | 3 | 6 |
| Calcium <1.75 mmol/L | 0 | 3 |
| Calcium >2.88 mmol/L | 0 | 0 |
| Chloride <75 mmol/L | 0 | 0 |
| Chloride >126 mmol/L | 0 | 0 |
| Creatinine >177umol/L | 0 | 1 |
| GGT >3 U/L*ULN | 5 | 2 |
| Glucose <2.8 mmol/L | 0 | 0 |
| Glucose >19.4 mmol/L | 1 | 0 |
| Phosphate <0.52 mmol/L | 0 | 0 |
| Phosphate >2.10 mmol/L | 0 | 1 |
| Potassium <3 mmol/L | 1 | 0 |
| Potassium >6 mmol/L | 0 | 0 |
| Sodium <130 mmol/L | 0 | 0 |
| Sodium >150 mmol/L | 0 | 0 |
| Basophils >3(10^9/L)*ULN | 0 | 0 |
| Eosinophils >2(10^9/L)*ULN | 0 | 0 |
| Hematocrit (%) <0.8*LLN | 7 | 8 |
| Hematocrit (%) >1.2*ULN | 0 | 0 |
| Hemoglobin <0.8 g/L*LLN | 7 | 8 |
| Hemoglobin >1.2 g/L*ULN | 0 | 0 |
| Leukocytes <0.5 (10^9/L)*LLN | 3 | 7 |
| Leukocytes >1.5 (10^9/L)*ULN | 1 | 0 |
| Lymphocytes <0.5 (10^9/L)*LLN | 7 | 9 |
| Lymphocytes >1.5(10^9/L)*ULN | 0 | 0 |
| Monocytes >2 (10^9/L)*ULN | 0 | 1 |
| Neutrophils <0.5(10^9/L)*LLN | 0 | 3 |
| Neutrophils >1.5 (10^9/L)*ULN | 1 | 1 |
| Platelets <75(10^9/L) | 8 | 9 |
| Platelets >600(10^9/L) | 0 | 0 |
Vital signs included heart rate, respiratory rate, systolic and diastolic blood pressure, temperature and weight. The vital sign values outside the range: systolic blood pressure (SBP) \<85 mmHg and change from Baseline (BL) \<=-20 mmHg, \>180 mmHg and change from Baseline \>=20 mmHg,diastolic blood pressure (DBP) \<50 mmHg and change from Baseline \<=-15 mmHg, \>110 mmHg and change from Baseline \>=15 mmHg, heart rate \<50 beats per minute (bpm),\>120 beats per minute, temperature \<35.6 Degree C, \>37.7 Degree C and weight change from Baseline \<=-7 % and weight change from Baseline \>=7 % assessed during treatment period were considered markedly abnormal.
| Participants | Vedolizumab 300 mg | Vedolizumab 600 mg |
|---|---|---|
| SBP <85 mmHg and change from BL <=-20 mmHg | 0 | 0 |
| SBP >180 mmHg and change from BL >=20 mmHg | 1 | 0 |
| DBP <50 mmHg and change from BL<=-15 mmHg | 0 | 0 |
| DBP >110 mmHg and change from BL>=15 mmHg | 0 | 0 |
| Heart Rate <50 bpm | 0 | 0 |
| Heart Rate >120 bpm | 0 | 1 |
| Temperature <35.6 Degree C | 1 | 3 |
| Temperature >37.7 Degree C | 0 | 0 |
| Weight change from BL <=-7 % | 4 | 2 |
| Weight change from BL >=7 % | 3 | 1 |
| ug/mL | Vedolizumab 300 mg | Vedolizumab 600 mg |
|---|---|---|
| Ctrough: Trough Serum Concentrations of Vedolizumab | 40.2 ± 37.2 | 12.3 ± 5.49 |
Collected over From first dose of study drug to 18 weeks after the last dose of study drug (Up to approximately 32 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vedolizumab 300 mg | 4/8 (50%) | 6/8 (75%) | 8/8 (100%) |
| Vedolizumab 600 mg | 9/9 (100%) | 9/9 (100%) | 9/9 (100%) |
| Event | Vedolizumab 300 mg | Vedolizumab 600 mg |
|---|---|---|
| Graft versus host diseaseImmune system disorders | 0/8 | 3/9 |
| SepsisInfections and infestations | 2/8 | 1/9 |
| DiarrhoeaGastrointestinal disorders | 1/8 | 1/9 |
| Rectal haemorrhageGastrointestinal disorders | 1/8 | 0/9 |
| DeathGeneral disorders | 1/8 | 0/9 |
| Acute graft versus host disease in intestineImmune system disorders | 1/8 | 0/9 |
| Bacterial sepsisInfections and infestations | 1/8 | 0/9 |
| Enterococcal sepsisInfections and infestations | 1/8 | 1/9 |
| Pneumonia necrotisingInfections and infestations | 1/8 | 0/9 |
| UrosepsisInfections and infestations | 1/8 | 0/9 |
| Event | Vedolizumab 300 mg | Vedolizumab 600 mg |
|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 3/8 | 5/9 |
| AnaemiaBlood and lymphatic system disorders | 4/8 | 3/9 |
| NauseaGastrointestinal disorders | 3/8 | 0/9 |
| Oedema peripheralGeneral disorders | 3/8 | 3/9 |
| HyperglycaemiaMetabolism and nutrition disorders | 3/8 | 2/9 |
| NeutropeniaBlood and lymphatic system disorders | 1/8 | 3/9 |
| FatigueGeneral disorders | 0/8 | 3/9 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 2/8 | 3/9 |
| HypomagnesaemiaMetabolism and nutrition disorders | 1/8 | 3/9 |
| DizzinessNervous system disorders | 1/8 | 3/9 |
Safety analysis set (SAS) included all participants who received any amount of the study drug.
| Age, Continuous(years) | Vedolizumab 300 mg | Vedolizumab 600 mg | Total |
|---|---|---|---|
| Mean | 54.1 ± 10.45 | 59.0 ± 10.87 | 56.7 ± 10.64 |
| Sex: Female, Male(Participants) | Vedolizumab 300 mg | Vedolizumab 600 mg | Total |
|---|---|---|---|
| Female | 6 | 4 | 10 |
| Male | 2 | 5 | 7 |
| Race/Ethnicity, Customized(Participants) | Vedolizumab 300 mg | Vedolizumab 600 mg | Total |
|---|---|---|---|
| Not Hispanic or Latino | 6 | 9 | 15 |
| Not Reported | 2 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Vedolizumab 300 mg | Vedolizumab 600 mg | Total |
|---|---|---|---|
| White | 7 | 9 | 16 |
| Not Reported | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Vedolizumab 300 mg | Vedolizumab 600 mg | Total |
|---|---|---|---|
| Belgium | 2 | 2 | 4 |
| France | 3 | 1 | 4 |
| Norway | 0 | 1 | 1 |
| United States | 3 | 5 | 8 |
| Height(cm) | Vedolizumab 300 mg | Vedolizumab 600 mg | Total |
|---|---|---|---|
| Mean | 170.3 ± 12.08 | 169.8 ± 7.87 | 170.0 ± 9.85 |
| Weight(kg) | Vedolizumab 300 mg | Vedolizumab 600 mg | Total |
|---|---|---|---|
| Mean | 76.40 ± 16.900 | 74.01 ± 22.255 | 75.14 ± 19.342 |
| Baseline Eastern Cooperative Oncology Group (ECOG) Status(Participants) | Vedolizumab 300 mg | Vedolizumab 600 mg | Total |
|---|---|---|---|
| 0 | 2 | 0 | 2 |
| 1 | 3 | 2 | 5 |
| 2 | 1 | 4 | 5 |
| 3 | 2 | 3 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Apr 2017 to primary completion in May 2018, 12 months.
Results were first posted in May 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab
Millennium Pharmaceuticals, Inc. →